Inhibitory effect of trapidil on human meningioma cell proliferation via interruption of autocrine growth stimulation
- 1 March 1993
- journal article
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery
- Vol. 78 (3), 463-469
- https://doi.org/10.3171/jns.1993.78.3.0463
Abstract
In a previous study, the authors demonstrated that meningioma cells secrete platelet-derived growth factor (PDGF)-like molecules that stimulate their own growth in an autocrine manner. Based on that finding, a study was undertaken to examine the effect of trapidil, a drug known to have an antagonistic action against PDGF, on cell proliferation of human meningiomas in culture. Trapidil showed a dose-dependent inhibition of meningioma cell proliferation in the absence of any exogenous mitogenic stimulation. The maximum effect was observed at a concentration of 100 micrograms/ml, with the decrease in cell growth ranging from 16% to 54% compared to control samples. Trapidil similarly inhibited the basal deoxyribonucleic acid (DNA) synthesis assessed by [3H]-thymidine incorporation in three of seven meningiomas. While the conditioned medium generated from meningioma cells remarkably stimulated the proliferation of meningioma cells (166% to 277% of control), this effect was strikingly inhibited by the addition of trapidil. Trapidil also inhibited conditioned medium-stimulated DNA synthesis, even when there was no effect on basal DNA synthesis. Furthermore, trapidil significantly inhibited the epidermal growth factor (EGF)-stimulated proliferation of meningioma cells. This inhibitory effect on EGF-stimulated cell proliferation was also observed in nontumorous fibroblasts, demonstrating that trapidil is not an antagonist specific to PDGF. The addition of trapidil (30 micrograms/ml) in combination with bromocriptine (1 microM) showed an additive inhibitory effect on the meningioma cell growth compared to trapidil or bromocriptine alone. The overall results suggest that trapidil exhibits an inhibitory effect on meningioma cell proliferation through blocking the mitogenic stimulation induced by autocrine or exogenous growth factors, and may be considered as a possible new approach to the medical treatment of meningiomas.Keywords
This publication has 40 references indexed in Scilit:
- Response of low-passage human malignant gliomas in vitro to stimulation and selective inhibition of growth factor-mediated pathwaysJournal of Neurosurgery, 1991
- Effect of steroids and antisteroids on human meningioma cells in primary cultureJournal of Steroid Biochemistry, 1989
- Effect of the antiprogesterone RU-38486 on meningioma implanted into nude miceJournal of Neurosurgery, 1987
- Hormone treatment of meningiomas: Lack of response to medroxyprogesterone acetate (MPA)Acta Neurochirurgica, 1986
- Antiestrogenic therapy of meningiomas—a pilot studySurgical Neurology, 1985
- Modulation of meningioma cell growth by sex steroid hormones in vitroJournal of Neurosurgery, 1985
- Estrogen and progesterone receptors in meningiomas in relation to clinical and pathologic featuresSurgical Neurology, 1983
- Presence of sex steroid hormone receptors in meningioma tissueSurgical Neurology, 1981
- A new approach to the treatment of atherosclerosis and trapidil as an antagonist to platelet-derived growth factorLife Sciences, 1981
- RADIATION THERAPY OF MENINGIOMASAmerican Journal of Roentgenology, 1975